Pharmacokinetics and clinical outcomes of nivolumab administered every 4 weeks in patients with advanced non-small-cell lung cancer: A four-case pilot study.
This pilot study evaluated the pharmacokinetics and clinical outcome of nivolumab, administered every 4 weeks to patients with advanced non-small-cell lung cancer. The interval of nivolumab administration was changed from 2 to 4 weeks in four patients in whom tumor growth had been controlled for more than 6 months. Pharmacokinetics and clinical outcomes of nivolumab were prospectively investigated. The estimated steady-state nivolumab mean plasma concentration (±standard deviation) of each interval in the four patients was 53.1 (±15.0) at 4 weeks and 105.2 (±29.5) μg/mL at 2 weeks. No disease progression was observed in three patients for at least 1 year after the interval change; however, one patient developed interstitial lung disease within 5.6 months after the change. In conclusion, the pharmacological effects of nivolumab continued with doses administered less frequently than the standard schedule. Nevertheless, further research on nivolumab administration intervals is necessary.
['Irie|Kei|K|', 'Okada|Akira|A|', 'Fukushima|Shoji|S|', 'Takase|Naoto|N|', 'Katakami|Nobuyuki|N|']
D000074322:Antineoplastic Agents, Immunological D002289:Carcinoma, Non-Small-Cell Lung D006801:Humans D008175:Lung Neoplasms D000077594:Nivolumab D010865:Pilot Projects
Pharmacokinetics Non-small-cell lung cancer Administration interval 4-Week interval nivolumab